SDH-Engine

Drug Repurposing Engine

DashboardDrug CandidatesAI HypothesesResearch FeedClinical TrialsAbout / Methods

Targeting SDH-deficient GIST, paraganglioma, pheochromocytoma, RCC

This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

4 candidates mapped to SDH-deficient disease pathways

All (38)established (6)clinical trial (5)preclinical (14)theoretical (13)
Sunitinib

Sutent

established

Multi-kinase inhibitor (VEGFR/PDGFR/KIT)

Vegf SignalingMtor Pi3k Akt
GISTPPGL/PCCRCC
Evidence Score
78
FDA Approved1 trial
Regorafenib

Stivarga

established

Multi-kinase inhibitor (VEGFR/KIT/PDGFR/FGFR/RAF)

Vegf SignalingMtor Pi3k Akt
GISTRCC
Evidence Score
58
FDA Approved
Everolimus

Afinitor

preclinical

mTOR inhibitor (rapalog)

Mtor Pi3k Akt
All SDH tumors
Evidence Score
55
FDA Approved
Metformin

Glucophage

preclinical

Biguanide / AMPK activator

Mtor Pi3k AktOxidative Stress Ros
All SDH tumors
Evidence Score
40
FDA Approved